SELLAS Life Sciences Group, Inc. (SLS) NASDAQ
4.88
+0(+0.00%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
4.88
+0(+0.00%)
Currency In USD
| Previous Close | 4.88 |
| Open | 4.82 |
| Day High | 4.92 |
| Day Low | 4.73 |
| 52-Week High | 6.14 |
| 52-Week Low | 1.36 |
| Volume | 3.26M |
| Average Volume | 6.4M |
| Market Cap | 695.12M |
| PE | -19.52 |
| EPS | -0.25 |
| Moving Average 50 Days | 4.83 |
| Moving Average 200 Days | 2.91 |
| Change | 0 |
SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe
GlobeNewswire Inc.
Jan 14, 2026 1:30 PM GMT
Supports capital-efficient expansion of the SLS009 clinical program into frontline AML, enabling broader U.S. and European patient enrollment U.S. enrollment evaluating SLS009 in combination with AZA/VEN in newly diagnosed AML with high-risk features
SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML)
GlobeNewswire Inc.
Dec 29, 2025 1:35 PM GMT
Contract Research Organization for the REGAL trial has informed the Company that 72 events have occurred in the trial as of December 26, 2025; SELLAS remains blinded to trial outcomesTiming of the final analysis is event-driven, and SELLAS will annou
SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025
GlobeNewswire Inc.
Dec 07, 2025 11:00 PM GMT
SLS009 in combination with AZA/VEN achieved a 46% overall response rate across all cohorts, a 58% overall response rate in patients with one prior line of therapy, and encouraging survival outcomes in heavily-pretreated AML-MR following prior VEN-bas